Prophylactic ciprofloxacin treatment prevented high mortality, and modified systemic and intestinal immune function in tumour-bearing rats receiving dose-intensive CPT-11 chemotherapy

British Journal of Cancer

Volumn 100, Issue 10, 2009, Pages 1581-1588

  Xue, H ^a   Field, C J ^a   Sawyer, M B ^a   Dieleman, L A ^a   Baracos, V E ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Ciprofloxacin; CPT 11; Gut; Immunity; Infectious complication

Indexed keywords

CIPROFLOXACIN; CONCANAVALIN A; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; IRINOTECAN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL INFECTION; CELL PROLIFERATION; COLON TUMOR; CONTROLLED STUDY; DIARRHEA; DRUG EFFECT; FEMALE; IMMUNE FUNCTION TEST; LYMPH NODE CELL; MESENTERY LYMPH NODE; MORTALITY; MUSCLE ATROPHY; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; RAT; WEIGHT REDUCTION;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTIBIOTIC PROPHYLAXIS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CARCINOMA; CIPROFLOXACIN; COLORECTAL NEOPLASMS; DIARRHEA; FEMALE; IMMUNITY, MUCOSAL; INTESTINAL MUCOSA; LYMPHATIC METASTASIS; NEOPLASM TRANSPLANTATION; RATS; RATS, INBRED F344; SPLEEN; SURVIVAL ANALYSIS;

EID: 67349251525     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605051     Document Type: Article

References (54)

1. Adamik B, Zimecki M, Wlaszczyk A, Kubier A (1997) Immunological status of septic and trauma patients. II. Proliferative response and production of interleukin 6 and tumor necrosis factor alpha by peripheral blood mononuclear cells from septic survivor, nonsurvivor and trauma patients: a correlation with the survival rate. Arch Immunol Ther Exp (Warsz) 45: 277-284
2. Ayala A, Deol ZK, Lehman DL, Herdon CD, Chaudry IH (1994) Polymicrobial sepsis but not low-dose endotoxin infusion causes decreased splenocyte IL-2/IFN-gamma release while increasing IL-4/IL-10 production. J Surg Res 56: 579-585
3. Ayala A, Knotts JB, Ertel W, Perrin MM, Morrison MH, Chaudry IH (1993a) Role of interleukin 6 and transforming growth factor-beta in the induction of depressed splenocyte responses following sepsis. Arch Surg 128: 89-94
4. Ayala A, Meldrum DR, Perrin MM, Chaudry IH (1993b) The release of transforming growth factor-beta following haemorrhage: its role as a mediator of host immunosuppression. Immunology 79: 479-484
5. Bailly S, Fay M, Ferrua B, Gougerot-Pocidalo MA (1991) Ciprofloxacin treatment in vivo increases the ex vivo capacity of lipopolysaccharide- stimulated human monocytes to produce IL-1, IL-6 and tumour necrosis factor-alpha. Clin Exp Immunol 85: 331-334
6. Bendtzen K (1988) Interleukin 1, interleukin 6 and tumor necrosis factor in infection, inflammation and immunity. Immunol Lett 19: 183-191
7. Bone RC, Grodzin CJ, Balk RA (1997) Sepsis: a new hypothesis for pathogenesis of the disease process. Chest 112: 235-243
8. Bradley LM, Watson SR, Swain SL (1994) Entry of naive CD4 T cells into peripheral lymph nodes requires L-selectin. J Exp Med 180: 2401-2406
9. Busca A, Lovisone E, Aliberti S, Locatelli F, Serra A, Scaravaglio P, Omede P, Rossi G, Cirillo D, Barbui A, Ghisetti V, Dall'Omo AM, Falda M (2003) Immune reconstitution and early infectious complications following nonmyeloablative hematopoietic stem cell transplantation. Hematology 8: 303-311
10. Cao S, Black JD, Troutt AB, Rustum YM (1998) Interleukin 15 offers selective protection from irinotecan-induced intestinal toxicity in a preclinical animal model. Cancer Res 58: 3270-3274
11. Cavaillon JM (2002) 'Septic Plasma' an immunosuppressive milieu. Am J Respir Crit Care Med 166: 1417-1418
12. Dalhoff A (2005) Immunomodulatory activities of fluoroquinolones. Infection 33(Suppl 2): 55 - 70
13. Dalhoff A, Shalit I (2003) Immunomodulatory effects of quinolones. Lancet Infect Dis 3: 359-371
14. de Koning BA, van Dieren JM, Lindenbergh-Kortleve DJ, van der Sluis M, Matsumoto T, Yamaguchi K, Einerhand AW, Samsom JN, Pieters R, Nieuwenhuis EE (2006) Contributions of mucosal immune cells to methotrexate-induced mucositis. Int Immunol 18: 941-949
15. De Simone C, Baldinelli L, Ferrazzi M, De Santis S, Pugnaloni L, Sorice F (1986) Influence of ofloxacin, norfloxacin, nalidixic acid, pyromidic acid and pipemidic acid on human gamma-interferon production and blastogenesis. J Antimicrob Chemother 17: 811-814
16. Dulude G, Brochu S, Fontaine P, Baron C, Gyger M, Roy DC, Perreault C (1997) Thymic and extrathymic differentiation and expansion of T lymphocytes following bone marrow transplantation in irradiated recipients. Exp Hematol 25: 992 - 1004
17. Field CJ, Thomson CA, Van Aerde JE, Parrott A, Euler A, Lien E, Clandinin MT (2000) Lower proportion of CD45R0+ cells and deficient interleukin-10 production by formula-fed infants, compared with human-fed, is corrected with supplementation of long-chain polyunsaturated fatty acids. J Pediatr Gastroenterol Nutr 31: 291-299
18. Field CJ, Van Aerde A, Drager KL, Goruk S, Basu T (2006) Dietary folate improves age-related decreases in lymphocyte function. J Nutr Biochem 17: 37-44
19. Fujii Y, Okumura M, Inada K, Nakahara K, Matsuda H (1992) CD45 isoform expression during T cell development in the thymus. Eur J Immunol 22: 1843-1850
20. Gafter-Gvili A, Fraser A, Paul M, Leibovici L (2005) Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 142: 979-995
21. Garside P, Millington O, Smith KM (2004) The anatomy of mucosal immune responses. Ann N Y Acad Sci 1029: 9-15
22. Gibson RJ, Bowen JM, Inglis MR, Cummins AG, Keefe DM (2003) Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. J Gastroenterol Hepatol 18: 1095-1100
23. Gollapudi SV, Prabhala RH, Thadepalli H (1986) Effect of ciprofloxacin on mitogen-stimulated lymphocyte proliferation. Antimicrob Agents Chemother 29: 337-338
24. Hakim FT, Cepeda R, Kaimei S, Mackall CL, McAtee N, Zujewski J, Cowan K, Gress RE (1997) Constraints on CD4 recovery postchemotherapy in adults: thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells. Blood 90: 3789-3798
25. Harris J, Sengar D, Stewart T, Hyslop D (1976) The effect of immunosuppressive chemotherapy on immune function in patients with malignant disease. Cancer 37: 1058 - 1069
26. Hayday A, Viney JL (2000) The ins and outs of body surface immunology. Science 290: 97-100
27. Hecht JR (1998) Gastrointestinal toxicity or irinotecan. Oncology (Williston Park) 12: 72 - 78
28. Henon PR, Liang H, Beck-Wirth G, Eisenmann JC, Lepers M, Wunder E, Kandel G (1992) Comparison of hematopoietic and immune recovery after autologous bone marrow or blood stem cell transplants. Bone Marrow Transplants. 285-291
29. Hotchkiss RS, Karl IE (2003) The pathophysiology and treatment of sepsis. N Engl J Med 348: 138 - 150
30. Jackson AL, Matsumoto H, Janszen M, Maino V, Blidy A, Shye S (1990) Restricted expression of p55 interleukin 2 receptor (CD25) on normal T cells. Clin Immunol Immunopathol 54: 126-133
31. Katsuno G, Takahashi HK, Iwagaki H, Mizuno K, Yagi T, Mori S, Saito S, Yoshino T, Nishibori M, Tanaka N (2006) The immunosuppressive effects of ciprofloxacin during human mixed lymphocyte reaction. Clin Immunol 119: 110-119
32. Leibovici L, Paul M, Cullen M, Bucaneve G, Gafter-Gvili A, Fraser A, Kern WV (2006) Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. Cancer 107: 1743-1751
33. Lum JB, Infante AJ, Makker DM, Yang F, Bowman BH (1986) Transferrin synthesis by inducer T lymphocytes. J Clin Invest 77: 841-849
34. Mackall CL, Fleisher TA, Brown MR, Magrath IT, Shad AT, Horowitz ME, Wexler LH, Adde MA, McClure LL, Gress RE (1994) Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 84: 2221-2228
35. Munford RS, Pugin J (2001) Normal responses to injury prevent systemic inflammation and can be immunosuppressive. Am J Respir Crit Care Med 163: 316-321
36. Murtaugh MP, Foss DL (2002) Inflammatory cytokines and antigen presenting cell activation. Vet Immunol Immunopathol 87: 109-121
37. Nussler NC, Stange B, Nussler AK, Settmacher U, Langrehr JM, Neuhaus P, Hoffman RA (2001) Upregulation of intraepithelial lymphocyte (IEL) function in the small intestinal mucosa in sepsis. Shock 16: 454-458
38. O'Sullivan ST, Lederer JA, Horgan AF, Chin DH, Mannick JA, Rodrick ML (1995) Major injury leads to predominance of the T helper-2 lymphocyte phenotype and diminished interleukin-12 production associated with decreased resistance to infection. Ann Surg 222: 482-490; discussion 490-482
39. Oberholzer A, Oberholzer C, Moldawer LL (2001) Sepsis syndromes: understanding the role of innate and acquired immunity. Shock 16: 83 - 96
40. Powell JD (2006) The induction and maintenance of T cell anergy. Clin Immunol 120: 239-246
41. Reddy M, Eirikis E, Davis C, Davis HM, Prabhakar U (2004) Comparative analysis of lymphocyte activation marker expression and cytokine secretion profile in stimulated human peripheral blood mononuclear cell cultures: an in vitro model to monitor cellular immune function. J Immunol Methods 293: 127-142
42. Riesbeck K, Forsgren A (1994) Increased interleukin 2 transcription in murine lymphocytes by ciprofloxacin. Immunopharmacology 27: 155 - 164
43. Rothenberg ML (2001) Irinotecan (CPT-11): recent developments and future directions - colorectal cancer and beyond. Oncologist 6: 66 - 80
44. Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S (2001) Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 19: 3801-3807
45. Rutella S, Rumi C, Laurenti L, Pierelli L, Sora F, Sica S, Leone G (2000) Immune reconstitution after transplantation of autologous peripheral CD34+ cells: analysis of predictive factors and comparison with unselected progenitor transplants. Br J Haematol 108: 105-115
46. Salmeron A, Borroto A, Fresno M, Crumpton MJ, Ley SC, Alarcon B (1995) Transferrin receptor induces tyrosine phosphorylation in T cells and is physically associated with the TCR zeta-chain. J Immunol 154: 1675-1683
47. Trifan OC, Durham WF, Salazar VS, Horton J, Levine BD, Zweifel BS, Davis TW, Masferrer JL (2002) Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res 62: 5778-5784
48. Urbaschek R, Urbaschek B (1990) The mediation of endotoxin-induced beneficial effects by cytokines. Adv Exp Med Biol 256: 549-556
49. Van der Meide PH, Schellekens H (1996) Cytokines and the immune response. Biotherapy 8: 243 - 249
50. Wang W, Smail N, Wang P, Chaudry IH (1998) Increased gut permeability after hemorrhage is associated with upregulation of local and systemic IL-6. J Surg Res 79: 39-46
51. Wendelbo O, Nesthus I, Sjo M, Paulsen K, Ernst P, Bruserud O (2004) Functional characterization of T lymphocytes derived from patients with acute myelogenous leukemia and chemotherapy-induced leukopenia. Cancer Immunol Immunother 53: 740-747
52. Wiseman LR, Markham A (1996) Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. Drugs 52: 606-623
53. Xue H, Sawyer MB, Field CJ, Dieleman LA, Baracos VE (2007) Nutritional modulation of antitumor efficacy and diarrhea toxicity related to irinotecan chemotherapy in rats bearing the Ward colon tumor. Clin Cancer Res 13: 7146-7154
54. Zhao J, Huang L, Belmar N, Buelow R, Fong T (2004) Oral RDP58 allows CPT-11 dose intensification for enhanced tumor response by decreasing gastrointestinal toxicity. Clin Cancer Res 10: 2851-2859